Here are six updates on GI companies from the past week:
Creo Medical Group's Speedboat RS2 device and Croma platform received FDA 510(k) clearance.
RedHill Biopharma entered into a commercialization agreement with ParaPRO to promote RedHill's Esomeprazole Strontium Delayed-Release capsules.
TopConsumerReviews.com awarded Bowtrol a five-star rating based on consumer feedback.
CDx Diagnostics' Wats3D detected high-grade dysplasia and esophageal adenocarcinomas at a 400 percent higher rate when compared to the standard Seattle protocol random forceps biopsy.
Caret Pharma is acquiring Moberg Pharma AB's Fiber Choice, a line of prebiotic fiber-based dietary supplements.
Qiagen and Clinical Genomics combined the PAXgene Blood ccfDNA Tube sample collection system into Clinical Genomics' Colvera colorectal cancer recurrence assay.